trending Market Intelligence /marketintelligence/en/news-insights/trending/a8GXMyFUT0YNaGvoIW3GTw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

J&J files for expanded use of psoriasis drug Tremfya in EU

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


J&J files for expanded use of psoriasis drug Tremfya in EU

Johnson & Johnson filed an application with the European Medicines Agency seeking approval for expanded use of its medicine Tremfya to treat adult patients with active psoriatic arthritis.

Psoriatic arthritis is a type of arthritis that affects some people who have psoriasis — a condition that features red patches of skin topped with silvery scales. Symptoms of psoriatic arthritis include joint pain, stiffness and swelling. It is estimated that up to a third of the 14 million people living with psoriasis in Europe will also develop psoriatic arthritis, J&J said in an Oct. 23 press release.

Tremfya, or guselkumab, works by selectively inhibiting the p19 subunit of interleukin-23 protein and gene, which plays a role in the growth of the disease. J&J said if Tremfya is approved, it will become the first medicine of its kind in the EU to treat active psoriatic arthritis.

J&J said the submission was backed by positive data from two phase 3 studies — Discover-1 and Discover-2. The company has already applied with the U.S. Food and Drug Administration for the expanded use of Tremfya for the same indication.

Tremfya is approved in the U.S., EU, Canada, and several other countries to treat plaque psoriasis and in Japan to treat psoriasis, psoriatic arthritis and a chronic skin condition called palmoplantar pustulosis.